GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » Debt-to-Revenue

Tci Gene (ROCO:6879) Debt-to-Revenue : 0.02 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tci Gene Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Tci Gene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$6.8 Mil. Tci Gene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$0.0 Mil. Tci Gene's annualized Revenue for the quarter that ended in Dec. 2023 was NT$368.0 Mil. Tci Gene's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.02.


Tci Gene Debt-to-Revenue Historical Data

The historical data trend for Tci Gene's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene Debt-to-Revenue Chart

Tci Gene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
- - 0.02 0.01 0.02

Tci Gene Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.01 0.03 0.02

Competitive Comparison of Tci Gene's Debt-to-Revenue

For the Biotechnology subindustry, Tci Gene's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tci Gene's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tci Gene's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tci Gene's Debt-to-Revenue falls into.



Tci Gene Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Tci Gene's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.795 + 0) / 333.855
=0.02

Tci Gene's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.795 + 0) / 367.984
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Tci Gene Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tci Gene's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tci Gene (ROCO:6879) Business Description

Traded in Other Exchanges
N/A
Address
No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines